Organon dans l'actualité
Thérapies et produits de santé
Tamtam a trouvé 20 articles récents sur Organon.
- Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
- Henlius
- Sun Pharma completes $11.75bn financing syndication for Organon acquisition
- Organon & Co. Shareholders Clear Sun Pharma Merger Deal
- Organon commits more than $1.3 million towards enabling choices and resilient demographies with UNFPA
- Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
- White & Case advises Sun Pharma on US$11.75 billion acquisition of Organon
- Sun Pharma to buy Organon for more than $11 billion
- Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
- Organon: Deep Value With No Clear Catalysts (NYSE:OGN)
- Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts
- TetraScience and Organon Collaborate to Modernize Quality Control Data Management
- Laborie Expands Portfolio with Acquisition of JADA System from Organon
- Organon Details Nexplanon Sales Practice Issue
- Organon CEO exits, company goes on hunt for successor as internal probe turns up 'improper' Nexplanon sales tactics
- Organon divests Jada System, sends 100 employees to Laborie Medical Technologies in $465M deal
- Organon and Henlius see FDA approval of Poherdy for HER2-positive breast cancers
- Organon and UNFPA advance reproductive health services
- Henlius, Organon win US FDA approval of first Perjeta biosimilar
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Organon ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires